BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19626699)

  • 1. Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations.
    Yang XR; Pfeiffer RM; Wheeler W; Yeager M; Chanock S; Tucker MA; Goldstein AM
    Int J Cancer; 2009 Dec; 125(12):2912-7. PubMed ID: 19626699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations.
    Yang XR; Liang X; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM
    Fam Cancer; 2010 Dec; 9(4):625-33. PubMed ID: 20574843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variants in DNA repair genes and the risk of cutaneous malignant melanoma in melanoma-prone families with/without CDKN2A mutations.
    Liang XS; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM; Yang XR
    Int J Cancer; 2012 May; 130(9):2062-6. PubMed ID: 21671477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomere length and the risk of cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations.
    Burke LS; Hyland PL; Pfeiffer RM; Prescott J; Wheeler W; Mirabello L; Savage SA; Burdette L; Yeager M; Chanock S; De Vivo I; Tucker MA; Goldstein AM; Yang XR
    PLoS One; 2013; 8(8):e71121. PubMed ID: 23990928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
    Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
    J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of genetic variants in CDK6 and XRCC1 with the risk of dysplastic nevi in melanoma-prone families.
    Liang X; Pfeiffer RM; Li WQ; Brossard M; Burke LS; Wheeler W; Calista D; Fargnoli MC; Ghiorzo P; Peris K; Bianchi-Scarra G; Chaudru V; Zelenika D; Maeder D; Burdette L; Yeager M; Chanock S; Landi MT; Demenais F; Tucker MA; Goldstein AM; Yang XR
    J Invest Dermatol; 2014 Feb; 134(2):481-487. PubMed ID: 23892592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LINE-1 methylation in peripheral blood and the risk of melanoma in melanoma-prone families with and without CDKN2A mutations.
    Hyland PL; Burke LS; Pfeiffer RM; Mirabello L; Tucker MA; Goldstein AM; Yang XR
    Melanoma Res; 2013 Feb; 23(1):55-60. PubMed ID: 23222549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN2A variants in a population-based sample of Queensland families with melanoma.
    Aitken J; Welch J; Duffy D; Milligan A; Green A; Martin N; Hayward N
    J Natl Cancer Inst; 1999 Mar; 91(5):446-52. PubMed ID: 10070944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.
    Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T
    J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.
    Aoude LG; Gartside M; Johansson P; Palmer JM; Symmons J; Martin NG; Montgomery GW; Hayward NK
    Twin Res Hum Genet; 2015 Apr; 18(2):126-33. PubMed ID: 25787093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene.
    Puig S; Ruiz A; Castel T; Volpini V; Malvehy J; Cardellach F; Lynch M; Mascaro JM; Estivill X
    Hum Genet; 1997 Dec; 101(3):359-64. PubMed ID: 9439668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A.
    van der Rhee JI; Krijnen P; Gruis NA; de Snoo FA; Vasen HFA; Putter H; Kukutsch NA; Bergman W
    J Am Acad Dermatol; 2011 Aug; 65(2):281-288. PubMed ID: 21570156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric melanoma in melanoma-prone families.
    Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA
    Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of germline CDKN2A mutations in Slovenian cutaneous malignant melanoma families.
    Hocevar M; Avbelj M; Perić B; Zgajnar J; Besić N; Battelino T
    Croat Med J; 2006 Dec; 47(6):851-4. PubMed ID: 17167857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
    Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
    Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
    Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
    Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.
    Lesueur F; de Lichy M; Barrois M; Durand G; Bombled J; Avril MF; Chompret A; Boitier F; Lenoir GM; ; Bressac-de Paillerets B; Baccard M; Bachollet B; Berthet P; Bonadona V; Bonnetblanc JM; Caron O; Chevrant-Breton J; Cuny JF; Dalle S; Delaunay M; Demange L; De Quatrebarbes J; Doré JF; Frénay M; Fricker JP; Gauthier-Villars M; Gesta P; Giraud S; Gorry P; Grange F; Green A; Huiart L; Janin N; Joly P; Kérob D; Lasset C; Leroux D; Limacher JM; Longy M; Mansard S; Marrou K; Martin-Denavit T; Mateus C; Maubec E; Olivier-Faivre L; Orlandini V; Pujol P; Sassolas B; Stoppa-Lyonnet D; Thomas L; Vabres P; Venat L; Wierzbicka E; Zattara H
    Br J Cancer; 2008 Jul; 99(2):364-70. PubMed ID: 18612309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of germline PALB2 mutations in melanoma-prone families with CDKN2A mutations and pancreatic cancer.
    Yang XR; Jessop L; Myers T; Amundadottir L; Pfeiffer RM; Wheeler W; Pike KM; Yuenger J; Burdett L; Yeager M; Chanock SJ; Tucker MA; Goldstein AM
    Fam Cancer; 2011 Sep; 10(3):545-8. PubMed ID: 21614589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population-based prevalence of CDKN2A mutations in Utah melanoma families.
    Eliason MJ; Larson AA; Florell SR; Zone JJ; Cannon-Albright LA; Samlowski WE; Leachman SA
    J Invest Dermatol; 2006 Mar; 126(3):660-6. PubMed ID: 16397522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.